Date | Insider | Price | Amount |
---|---|---|---|
7-17-2023 Insider Buy |
Carl L. Gordon Director and >10% Owner |
$3.05 CAGR » |
$1,463,792.60 479,932 shares |
7-17-2023 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$3.05 CAGR » |
$1,463,792.60 479,932 shares |
7-17-2023 Insider Buy |
Foresite Capital Management V, LLC >10% Owner |
$2.97 CAGR » |
$2,079,000.00 700,000 shares |
12-29-2022 Insider Buy |
Foresite Capital Management V, LLC >10% Owner |
$5.00 CAGR » |
$2,500,000.00 500,000 shares |
11-30-2022 Insider Buy |
Bradford D. Dahms Chief Financial Officer |
$6.66 CAGR » |
$10,000.07 1,502 shares |
11-7-2022 Insider Buy |
Carl L. Gordon Director and >10% Owner |
$5.21 CAGR » |
$1,000,320.00 192,000 shares |
11-7-2022 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$5.21 CAGR » |
$1,000,320.00 192,000 shares |
12-30-2022 Insider Buy |
Donald J. Hayden Jr. Director |
$5.00 CAGR » |
$49,989.11 10,000 shares |
11-11-2022 Insider Buy |
Timothy P. Clackson President and CEO |
$6.80 CAGR » |
$16,995.00 2,500 shares |
1-21-2022 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$9.97 CAGR » |
$1,578,717.49 158,417 shares |
1-21-2022 Insider Buy |
Carl L. Gordon Director and >10% Owner |
$9.97 CAGR » |
$1,578,717.49 158,417 shares |
1-13-2022 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$9.90 CAGR » |
$442,750.42 44,717 shares |
1-13-2022 Insider Buy |
Carl L. Gordon Director and >10% Owner |
$9.90 CAGR » |
$442,750.42 44,717 shares |
12-21-2021 Insider Buy |
Bradford D. Dahms Chief Financial Officer |
$10.15 CAGR » |
$20,000.00 1,970 shares |
12-21-2021 Insider Buy |
Timothy P. Clackson President and CEO |
$9.76 CAGR » |
$25,381.46 2,600 shares |
10-12-2021 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$16.00 CAGR » |
$10,000,000.00 625,000 shares |
10-12-2021 Insider Buy |
Springs Capital Management LP Rock >10% Owner |
$16.00 CAGR » |
$4,000,000.00 250,000 shares |
10-12-2021 Insider Buy |
William Shakespeare See Remarks |
$16.00 CAGR » |
$10,000.00 625 shares |
10-12-2021 Insider Buy |
Carl L. Gordon Director and >10% Owner |
$16.00 CAGR » |
$10,000,000.00 625,000 shares |
10-12-2021 Insider Buy |
Omega Fund VI, L.P. |
$16.00 CAGR » |
$3,000,000.00 187,500 shares |
8-7-2015 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$3485841.04 CAGR » |
$856,917,331,181.12 245,828 shares |
5-11-2015 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$1369264.00 CAGR » |
$117,180,243,856.00 85,579 shares |
3-2-2015 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$1673692.44 CAGR » |
$155,107,773,184.56 92,674 shares |
11-4-2014 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$12786524.16 CAGR » |
$10,644,218,756,137.00 832,456 shares |
8-11-2014 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$3912271.66 CAGR » |
$675,457,614,370.66 172,651 shares |
5-9-2014 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$8544835.30 CAGR » |
$2,715,292,313,281.00 317,770 shares |
2-11-2014 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$12850698.95 CAGR » |
$4,397,881,850,959.55 342,229 shares |
10-29-2013 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$4913613.18 CAGR » |
$641,093,852,434.14 130,473 shares |
7-30-2013 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$111850855.50 CAGR » |
$342,756,544,550,188.00 3,064,407 shares |
4-30-2013 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$6699215.43 CAGR » |
$1,296,720,236,277.09 193,563 shares |
2-15-2013 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$2567089.81 CAGR » |
$299,135,274,289.87 116,527 shares |
8-3-2012 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$28.21 CAGR » |
$8,923,782.14 316,334 shares |
5-16-2012 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$21.29 CAGR » |
$212,887,000.00 10,000,000 shares |
2-14-2012 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$18.12 CAGR » |
$1,603,040.16 88,468 shares |
11-1-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$22.23 CAGR » |
$1,298,476.53 58,411 shares |
8-2-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$19.71 CAGR » |
$2,019,604.86 102,466 shares |
5-3-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$25.60 CAGR » |
$6,689,254.40 261,299 shares |
11-1-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$22.23 CAGR » |
$1,298,476.53 58,411 shares |
8-2-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$19.71 CAGR » |
$2,019,604.86 102,466 shares |
5-3-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$25.60 CAGR » |
$6,689,254.40 261,299 shares |
2-18-2011 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$23.70 CAGR » |
$3,608,988.60 152,278 shares |
11-29-2010 Insider Buy |
Plc Glaxosmithkline >10% Owner |
$22.50 CAGR » |
$129,375,000.00 5,750,000 shares |
Also See: Institutional Holders of THRX
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 07/18/2023 | |
End date: | 02/14/2024 | |
Start price/share: | $2.82 | |
End price/share: | $4.06 | |
Dividends collected/share: | $0.00 | |
Total return: | 43.97% | |
Annualized Gain: | 76.06% | |
Starting investment: | $10,000.00 | |
Ending investment: | $14,397.00 | |
Years: | 0.58 |
THRX Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent THRX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding THRX
Free THRX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Other companies seeing insider buying close in time to when the THRX Insider Buying occurred are:
VBIV Insider Buying |